Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
-
Published:2019-11
Issue:11
Volume:30
Page:1796-1803
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Stintzing S.ORCID,
Wirapati P.,
Lenz H.-J.,
Neureiter D.,
Fischer von Weikersthal L.,
Decker T.,
Kiani A.,
Kaiser F.,
Al-Batran S.,
Heintges T.,
Lerchenmüller C.,
Kahl C.,
Seipelt G.,
Kullmann F.,
Moehler M.,
Scheithauer W.,
Held S.,
Modest D.P.,
Jung A.,
Kirchner T.,
Aderka D.,
Tejpar S.,
Heinemann V.
Subject
Oncology,Hematology
Cited by
142 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献